The research team of Bishal Gyawali, Associate Professor at Queen’s University, shared a post on X by The Lancet Oncology, about a paper he co-authored with colleagues:
“Don’t forget to read our article by Samuel Stevens, Laure-Anne Teuwen, and Bishal Gyawali in the November issue of The Lancet Oncology.”
Quoting The Lancet Oncology’s post:
“Our November issue is live.
Articles: breast cancer, NSCLC, prostate cancer, melanoma
Reviews: Tumour-infiltrating lymphocyte therapy in the era of genetic engineering AND AI for Response Assessment in Pediatric Neuro-Oncology (AI-RAPNO).”
Title: Overall survival assessment in cancer drug trials: a luxury or a necessity?
Authors: Samuel X Stevens, Laure-Anne Teuwen, Bishal Gyawali
You can read the Full Article in The Lancet Oncology.
More posts featuring Bishal Gyawali.
